Project Grant P01HL172741
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...
- This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
- The National Heart Lung and Blood Institute (NHLBI), under CFDA 93.837 Cardiovascular Diseases Research program, awarded a $129,600 Project Grant to Weill Medical College of Cornell University. The grant, with an award date of Sep 5, 2025 and an ultimate completion date of Aug 31, 2027, supports research to elucidate the molecular mechanisms of macrophage foam cell formation in the development of atherosclerotic plaques. The research aims to investigate the role of cholesterol transport proteins...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $450,000 in funding to Old Dominion University to investigate the relationship between disturbed sleep and the development of vulnerable atherosclerotic plaques. The primary objectives are to: 1) examine the role of NADPH-dependent oxidative stress in accelerating the formation of vulnerable atherosclerotic plaques in...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $787,267 to Yale University from January 1, 2025 to November 30, 2028 to conduct research aimed at determining whether genetic deletion of the DHCR24 enzyme in macrophages or hepatocytes can attenuate the progression of atherosclerosis. The project will exploit novel animal models and cutting-edge genomic and metabolomic technologies to evaluate the therapeutic...
- This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of innovative in vitro 3D atherosclerosis models and high-throughput drug screening assays by Endomimetics LLC. The key objectives are to create an automated, precise approach for fabricating advanced 3D vascular sheet and atherosclerosis models, which will enable efficient, high-throughput testing of drug...
- The University of Texas Southwestern Medical Center received a $772,275 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on how endothelial cell scavenger receptor class B type I (SR-BI) is regulated and interacts with other proteins to drive LDL transcytosis and promote atherosclerosis. The award, effective August 25, 2025 through May 31, 2029, aims to determine the mechanisms by which hypercholesterolemia and...
- This $787,453 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc. aims to develop a new lipid-lowering and anti-inflammatory siRNA therapy for more effective treatment of atherosclerotic cardiovascular disease (ASCVD). The project will leverage the researchers' recent discoveries on the biological roles of epsin endocytic adaptor proteins in regulating lipid metabolism and arterial...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $135,930 to the University of Connecticut Health Center to investigate the role of the TRPM7 ion channel in macrophage signaling and its impact on the development of atherosclerosis. The research aims to generate macrophage-specific TRPM7 deletion mice and subject them to a high-fat, Western diet atherosclerosis model to determine how in vivo TRPM7 deletion...
CELLULAR AND MOLECULAR MECHANISMS OF ATHEROSCLEROSIS - ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (CVD) REMAINS THE LEADING CAUSE OF DEATH WORLDWIDE AND SUBSTANTIAL RESIDUAL CVD RISK PERSISTS DESPITE EFFECTIVE LDL-CHOLESTEROL (LDL-C) LOWERING. IN THIS CONTEXT, WE PROPOSE AN INVESTIGATION OF MECHANISMS OF PLAQUE STABILIZATION AND DESTABILIZATION FOCUSED ON NOVEL FUNCTIONS OF MACROPHAGES (MF) AND VASCULAR STROMAL CELLS, AND THEIR CROSSTALK, IN MOUSE MODELS AND HUMAN CVD. OUR OVERARCHING HYPOTHESIS, PURSUED THROUGH THREE HIGHLY INTEGRATED PROJECTS AND TWO SCIENTIFIC CORES IS THAT INFLAMMATION AND THE EFFEROCYTOSIS-RESOLUTION CYCLE IN MACROPHAGES REGULATE PLAQUE STABILITY THROUGH CROSSTALK WITH OTHER MACROPHAGES AND STROMAL CELLS AND THAT DETAILED EXAMINATION OF THE CELL AND MOLECULAR MECHANISMS MAY PROVIDE OPPORTUNITIES FOR NOVEL CVD TREATMENTS, INCLUDING IN PATIENTS WITH CLONAL HEMATOPOIESIS, AN EMERGING CVD RISK FACTOR. TO ADDRESS THIS HYPOTHESIS, AIM 1 WILL ASSESS NOVEL GENES AND PATHWAYS REGULATING MACROPHAGE EFFEROCYTOSIS IN ATHEROSCLEROSIS AND MECHANISTICALLY BASED THERAPEUTIC APPROACHES TO IMPROVE EFFEROCYTOSIS AND STABILIZE PLAQUES. AIM 2 WILL INVESTIGATE THE IMPACT OF INFLAMMATORY CROSS-TALK FROM MFS TO STROMAL CELLS ON PLAQUE FIBROUS CAP FORMATION. AIM 3 WILL PURSUE TRANSLATIONAL RELEVANCE BY EXAMINING THE RELATIONSHIP OF CLONAL HEMATOPOIESIS MUTATIONS AND EFFEROCYTOSIS GENES TO FEATURES OF PLAQUE STABILITY USING HUMAN CAROTID PLAQUE SAMPLES FROM THE MUNICH VASCULAR BIOBANK. WE WILL PURSUE THESE OVERALL AIMS IN THREE HIGHLY INTEGRATED PROJECTS, AND TWO SCIENTIFIC CORES COORDINATED BY OUR ADMINISTRATIVE CORE. OUR PROGRAM WILL USE MOUSE MODELS OF DISEASE AND HUMAN ATHEROSCLEROTIC PLAQUES TO ASSESS MULTIPLE GENETIC AND THERAPEUTIC INTERVENTIONS DESIGNED TO STABILIZE PLAQUES AND REDUCE CVD RISK. THE PROJECTS WILL EXTENSIVELY LEVERAGE THE SCIENTIFIC CORES TO APPLY HARMONIZED BIOINFORMATIC METHODS TO SINGLE CELL -OMICS DATA (CORE B: BIOINFORMATICS AND BIOSTATISTICS) AND ATHEROSCLEROSIS PHENOTYPING OF MOUSE AND HUMAN LESIONS(CORE C: MOUSE AND HUMAN ATHEROSCLEROSIS TISSUE CORE). CROSS-CUTTING BIOLOGICAL AND TECHNICAL INNOVATIONS INCLUDE MICE THAT ACCURATELY MODEL CLONAL HEMATOPOIESIS, CELL LINEAGE TRACING MOUSE MODELS, ADVANCED BIOINFORMATICS FOR SC AND SPATIAL DATA, AND NEW SPATIAL TRANSCRIPTOMICS APPROACHES IN HUMAN CAROTID PLAQUES. COLLABORATION PERMEATES THE ENTIRE PPG AS A RESULT OF THREE YEARS OF PREPARATORY WORK AND PRELIMINARY STUDIES. EACH PROJECT ADDRESSES COMPLEMENTARY QUESTIONS THAT TOGETHER PROVIDE OPPORTUNITIES TO UNDERSTAND NEW CLINICALLY RELEVANT PARADIGMS OF ATHEROSCLEROSIS STABILITY AND INSTABILITY WITH THE EXPECTATION TO PROVIDE OPPORTUNITIES FOR NOVEL MECHANISM-BASED TARGETED THERAPEUTIC INTERVENTION TO REDUCE CVD BEYOND LDL-C LOWERING. THUS, OUR PROPOSED PPG IS MECHANISTICALLY, CLINICALLY AND TRANSLATIONALLY SIGNIFICANT AND RELEVANT TO PUBLIC HEALTH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.5m | 7/10/25 | ||
| Not listed | $2.1m | 6/14/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
2GG01898103PROJECT3S | Brigham & Womens Hospital Inc. | Project Grant P01HL172741 | $18.2k | 10/26/24 | |
1GG01898102S | Brigham & Womens Hospital Inc. | Project Grant P01HL172741 | $18.2k | 10/9/24 |